HUBEI GUANGJI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.3 CNY | -0.38% |
|
+0.57% | -33.67% |
| 2023 | Guangji Pharmaceutical Gets Nod to Produce Entecavir | MT |
| 2023 | Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| Sales 2021 | 837M 116M | Sales 2022 | 798M 110M | Capitalization | 2.71B 374M |
|---|---|---|---|---|---|
| Net income 2021 | 110M 15.18M | Net income 2022 | 50M 6.9M | EV / Sales 2021 | 3.32 x |
| Net Debt 2021 | 84.93M 11.72M | Net Debt 2022 | 232M 32.02M | EV / Sales 2022 | 3.69 x |
| P/E ratio 2021 |
24.5
x | P/E ratio 2022 |
53.6
x | Employees | 1,256 |
| Yield 2021 |
0.77% | Yield 2022 |
-
| Free-Float | 62.86% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.38% | ||
| 1 week | +0.57% | ||
| Current month | -10.17% | ||
| 1 month | -11.37% | ||
| 3 months | -23.19% | ||
| 6 months | -26.49% | ||
| Current year | -33.67% |
1 week
4.97
5.34
1 month
4.896.17
Current year
4.118.29
1 year
4.118.80
3 years
4.119.09
5 years
4.1110.08
10 years
4.1123.09
| Managers | Title | Age | Since |
|---|---|---|---|
Shu Ruan
CEO | Chief Executive Officer | 48 | 21-04-21 |
Ming Feng Hu
DFI | Director of Finance/CFO | 54 | 16-09-13 |
Zheng Dong Lu
CTO | Chief Tech/Sci/R&D Officer | 47 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qing Yuan Li
BRD | Director/Board Member | 47 | 21-04-21 |
Shao Zhi Guo
BRD | Director/Board Member | 55 | 15-01-05 |
Zhong Yi Ruan
PRN | Corporate Officer/Principal | 60 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 5.3 | -0.38% | 3,333,822 |
| 24-04-23 | 5.32 | +4.11% | 3,959,321 |
| 24-04-22 | 5.11 | +0.39% | 5,443,718 |
| 24-04-19 | 5.09 | -0.97% | 3,018,617 |
| 24-04-18 | 5.14 | -2.47% | 4,732,173 |
End-of-day quote Shenzhen S.E., April 23, 2024
More quotes
Hubei Guangji Pharmaceutical Co., Ltd. is the Chinese leader of pharmaceutical ingredients production. The group's activity is organized around four product families:
- vitamins: riboflavin and beta carotene;
- food supplements;
- fine chemistry products;
- medicinal preparations.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.67% | 259M | |
| +25.61% | 660B | |
| +23.91% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +12.77% | 219B | |
| -9.98% | 196B | |
| +6.92% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- 000952 Stock
